Today, after a successful phase 2 trial on a rare lung disease treatment, Arena Pharmaceuticals jumped almost 45% to just under $28. Should investors sell to lock in gains, or hold on? Todd Hagopian is taking profits, selling more than half of his ARNA position.
from Forbes Real Time http://www.forbes.com/sites/kenkam/2017/07/11/top-biotech-manager-sells-arena-pharmaceuticals-on-todays-big-gain/
via IFTTT
No comments:
Post a Comment